Meike de Wit

List of Publications by Year
in descending order

41 papers	1,610 citations	304743 22 h-index	454955 30 g-index
41 all docs	41 docs citations	41 times ranked	2729 citing authors

#	Article	IF	Citations
1	Quantitative analysis of CDX2 protein expression improves its clinical utility as a prognostic biomarker in stage II and III colon cancer. European Journal of Cancer, 2021, 144, 91-100.	2.8	14
2	Loss of enteric neuronal Ndrg4 promotes colorectal cancer via increased release of Nid1 and Fbln2. EMBO Reports, 2021, 22, e51913.	4.5	14
3	Lipopolysaccharideâ€regulated secretion of soluble and vesicleâ€based proteins from a panel of colorectal cancer cell lines. Proteomics - Clinical Applications, 2021, 15, 1900119.	1.6	2
4	Detection and characterization of lung cancer using cell-free DNA fragmentomes. Nature Communications, 2021, 12, 5060.	12.8	161
5	Clinical Validation of a Multitarget Fecal Immunochemical Test for Colorectal Cancer Screening. Annals of Internal Medicine, 2021, 174, 1224-1231.	3.9	16
6	Molecular characterization of colorectal adenomas reveals POFUT1 as a candidate driver of tumor progression. International Journal of Cancer, 2020, 146, 1979-1992.	5.1	32
7	Proteins in stool as biomarkers for nonâ€invasive detection of colorectal adenomas with high risk of progression. Journal of Pathology, 2020, 250, 288-298.	4.5	33
8	Can a biomarker triage test reduce colonoscopy burden in fecal immunochemical test screening?. Journal of Comparative Effectiveness Research, 2020, 9, 563-571.	1.4	0
9	CD31-positive microvessel density within adenomas of Lynch Syndrome patients is similar compared to adenomas of non-Lynch patients. Endoscopy International Open, 2019, 07, E701-E707.	1.8	3
10	Evaluation of Cancer-Associated DNA Copy Number Events in Colorectal (Advanced) Adenomas. Cancer Prevention Research, 2018, 11, 403-412.	1.5	15
11	Novel Stool-Based Protein Biomarkers for Improved Colorectal Cancer Screening. Annals of Internal Medicine, 2017, 167, 855.	3.9	39
12	Lumican and versican protein expression are associated with colorectal adenoma-to-carcinoma progression. PLoS ONE, 2017, 12, e0174768.	2.5	27
13	Abstract A04: Chromosomal aberrations implicated in colorectal adenoma to carcinoma progression as markers of high-risk colorectal adenomas. , 2017, , .		0
14	Abstract 1559: Proteogenomic analysis of alternative splicing in colorectal adenoma-to-carcinoma progression. , 2017, , .		0
15	Abstract 2208: Peptide-mediated 'miniprep' isolation of extracellular vesicles is suitable for high-throughput proteomics; method evaluation and application in colon cancer. , 2017, , .		0
16	Peptide-mediated â€˜miniprepâ€™ isolation of extracellular vesicles is suitable for high-throughput proteomics. EuPA Open Proteomics, 2016, 11, 11-15.	2.5	28
17	Abstract 3885: Peptide-mediated â€˜miniprepâ€™ isolation of extracellular vesicles for high-throughput proteomics; method evaluation and application in colon cancer. , 2016, , .		0
18	Abstract 3176: Improved colorectal cancer screening by new stool-based protein markers. , 2016, , .		0

#	Article	IF	Citations
19	MGL ligand expression is correlated to BRAF mutation and associated with poor survival of stage III colon cancer patients. Oncotarget, 2015, 6, 26278-26290.	1.8	39
20	Abstract 1563: Stool proteomics reveals novel candidate biomarkers for colorectal cancer screening. , 2015, , .		0
21	Colorectal cancer candidate biomarkers identified by tissue secretome proteome profiling. Journal of Proteomics, 2014, 99, 26-39.	2.4	81
22	The Role of SATB2 as a Diagnostic Marker for Tumors of Colorectal Origin. American Journal of Clinical Pathology, 2014, 141, 630-638.	0.7	116
23	Proteomics of differential extraction fractions enriched for chromatin-binding proteins from colon adenoma and carcinoma tissues. Biochimica Et Biophysica Acta - Proteins and Proteomics, 2014, 1844, 1034-1043.	2.3	8
24	Whole gel processing procedure for GeLC-MS/MS based proteomics. Proteome Science, 2013, 11, 17.	1.7	75
25	Proteomics in colorectal cancer translational research: Biomarker discovery for clinical applications. Clinical Biochemistry, 2013, 46, 466-479.	1.9	80
26	The cancer secretome, current status and opportunities in the lung, breast and colorectal cancer context. Biochimica Et Biophysica Acta - Proteins and Proteomics, 2013, 1834, 2242-2258.	2.3	95
27	Maspin is a marker for early recurrence in primary stage III and IV colorectal cancer. British Journal of Cancer, 2013, 109, 1636-1647.	6.4	41
28	Lumican and Versican Are Associated with Good Outcome in Stage II and III Colon Cancer. Annals of Surgical Oncology, 2013, 20, 348-359.	1.5	32
29	TPX2andAURKApromote 20q amplicon-driven colorectal adenoma to carcinoma progression. Gut, 2012, 61, 1568-1575.	12.1	118
30	CSE1L, DIDO1 and RBM39 in colorectal adenoma to carcinoma progression. Cellular Oncology (Dordrecht), 2012, 35, 293-300.	4.4	25
31	Cell surface proteomics identifies glucose transporter type 1 and prion protein as candidate biomarkers for colorectal adenoma-to-carcinoma progression. Gut, 2012, 61, 855-864.	12.1	82
32	Proximal Fluid Proteome Profiling of Mouse Colon Tumors Reveals Biomarkers for Early Diagnosis of Human Colorectal Cancer. Clinical Cancer Research, 2012, 18, 2613-2624.	7.0	46
33	BCL2L1 has a functional role in colorectal cancer and its protein expression is associated with chromosome 20q gain. Journal of Pathology, 2012, 226, 442-450.	4.5	39
34	Abstract 4523: Stool proteomics reveals new candidate biomarkers for colorectal cancer screening. Cancer Research, 2012, 72, 4523-4523.	0.9	5
35	Abstract 4526: Lumican and Versican predict good outcome in stage II and III colon cancer. , 2012, , .		0
36	Abstract 109:CSE1L, a 20q gain passenger that drives colorectal adenoma to carcinoma progression. , 2012, , .		0

#	Article	IF	Citations
37	SATB2 in Combination With Cytokeratin 20 Identifies Over 95% of all Colorectal Carcinomas. American Journal of Surgical Pathology, 2011, 35, 937-948.	3.7	209
38	Abstract 3042: TPX2 and AURKA promote 20q amplicon driven colorectal adenoma-to-carcinoma progression. , 2011, , .		0
39	Identification of key genes for carcinogenic pathways associated with colorectal adenoma-to-carcinoma progression. Tumor Biology, 2010, 31, 89-96.	1.8	74
40	Subnuclear Proteomics in Colorectal Cancer. Molecular and Cellular Proteomics, 2010, 9, 988-1005.	3.8	61
41	Abstract 4627: Proximal fluid proteome profiling of human colorectal cancer tissue reveals candidate biomarkers for CRC screening. , 2010, , .		0